CL2022001178A1 - Ligandos de la pseudoquinasa tyk2 - Google Patents

Ligandos de la pseudoquinasa tyk2

Info

Publication number
CL2022001178A1
CL2022001178A1 CL2022001178A CL2022001178A CL2022001178A1 CL 2022001178 A1 CL2022001178 A1 CL 2022001178A1 CL 2022001178 A CL2022001178 A CL 2022001178A CL 2022001178 A CL2022001178 A CL 2022001178A CL 2022001178 A1 CL2022001178 A1 CL 2022001178A1
Authority
CL
Chile
Prior art keywords
ligands
tyk2
tyk2 pseudokinase
pseudokinase ligands
pseudokinase
Prior art date
Application number
CL2022001178A
Other languages
English (en)
Inventor
Shendong Yuan
Raju Mohan
John Nuss
Jason Harris
Original Assignee
Ventyx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventyx Biosciences Inc filed Critical Ventyx Biosciences Inc
Publication of CL2022001178A1 publication Critical patent/CL2022001178A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

En este documento se describen LIGANDOS DE LA PSEUDOQUINASA TYK2 y métodos para utilizar LIGANDOS DE LA PSEUDOQUINASA TYK2 en el tratamiento de enfermedades, trastornos o afecciones. También se describen en este documento composiciones farmacéuticas que contienen tales compuestos.
CL2022001178A 2019-11-08 2022-05-04 Ligandos de la pseudoquinasa tyk2 CL2022001178A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962933179P 2019-11-08 2019-11-08
US202063046514P 2020-06-30 2020-06-30

Publications (1)

Publication Number Publication Date
CL2022001178A1 true CL2022001178A1 (es) 2023-02-03

Family

ID=75846491

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001178A CL2022001178A1 (es) 2019-11-08 2022-05-04 Ligandos de la pseudoquinasa tyk2

Country Status (14)

Country Link
US (2) US11753411B2 (es)
EP (1) EP4054581A4 (es)
JP (1) JP2022553841A (es)
KR (1) KR20220107194A (es)
CN (1) CN114929226A (es)
AU (1) AU2020378345A1 (es)
BR (1) BR112022008821A2 (es)
CA (1) CA3160637A1 (es)
CL (1) CL2022001178A1 (es)
CO (1) CO2022007814A2 (es)
IL (1) IL292785A (es)
MX (1) MX2022005563A (es)
TW (1) TW202128698A (es)
WO (1) WO2021092246A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220004641A (ko) 2019-03-26 2022-01-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나아제 리간드
TW202128698A (zh) 2019-11-08 2021-08-01 美商凡帝克斯生物科學公司 Tyk2假激酶配位體
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
US20240010654A1 (en) * 2022-07-06 2024-01-11 Ventyx Biosciences, Inc. Crystalline forms of a tyk2 inhibitor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
AU2004215481B2 (en) 2003-02-28 2010-11-11 Teijin Pharma Limited Pyrazolo(1,5-A)pyrimidine derivatives
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
NZ567151A (en) 2005-10-06 2012-03-30 Schering Corp Pyrazolo [1,5 -A] pyrimidine derivatives and their use for inhibiting Checkpoint kinases
US8591943B2 (en) 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
HUE035337T2 (en) 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
MD3371190T2 (ro) * 2015-11-06 2022-09-30 Incyte Corp Compuși heterociclici ca inhibitori PI3K-gamma
WO2018081488A1 (en) 2016-10-28 2018-05-03 Bristol-Myers Squibb Company Heterobicyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
AU2018230737B2 (en) 2017-03-08 2022-09-22 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20200360381A1 (en) 2017-05-15 2020-11-19 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
EP3658557A4 (en) 2017-07-28 2020-12-09 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
WO2020055636A1 (en) 2018-09-10 2020-03-19 Eli Lilly And Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
CA3115088A1 (en) 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
TWI800696B (zh) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
EP3920931A4 (en) 2019-02-07 2022-08-10 Ventyx Biosciences, Inc. TYK2 PSEUDOKINALIGANDS
EP3938369A4 (en) 2019-03-11 2023-01-25 Alumis Inc. TYK2 INHIBITORS AND USES THEREOF
KR20220004641A (ko) 2019-03-26 2022-01-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나아제 리간드
TW202128698A (zh) 2019-11-08 2021-08-01 美商凡帝克斯生物科學公司 Tyk2假激酶配位體

Also Published As

Publication number Publication date
TW202128698A (zh) 2021-08-01
EP4054581A1 (en) 2022-09-14
AU2020378345A1 (en) 2022-06-02
CO2022007814A2 (es) 2022-09-09
MX2022005563A (es) 2022-08-19
EP4054581A4 (en) 2023-11-22
WO2021092246A1 (en) 2021-05-14
US11753411B2 (en) 2023-09-12
US20230348478A1 (en) 2023-11-02
BR112022008821A2 (pt) 2022-08-23
US20210139486A1 (en) 2021-05-13
IL292785A (en) 2022-07-01
CN114929226A (zh) 2022-08-19
CA3160637A1 (en) 2021-05-14
KR20220107194A (ko) 2022-08-02
JP2022553841A (ja) 2022-12-26

Similar Documents

Publication Publication Date Title
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX2020013853A (es) Compuestos innovadores.
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990400A1 (ru) Соединения и композиции и их применение
PH12021550872A1 (en) Therapeutic compounds
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2021013602A (es) Inhibidores de jak.
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2022000712A (es) Moduladores de nlrp3.
CO2022014499A2 (es) Moduladores de nlrp3